Connor, Clark & Lunn Investment Management (CC&L)’s Tarsus Pharmaceuticals TARS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.73M	Sell	90,969 -20,468	-18%	-$1.31M	0.01%	681
2026 Q1	$7.82M	Sell	111,437 -61,838	-36%	-$4.32M	0.02%	545
2025 Q4	$14.2M	Buy	173,275 +69,464	+67%	+$5.19M	0.04%	366
2025 Q3	$6.17M	Buy	103,811 +43,316	+72%	+$2.13M	0.02%	523
2025 Q2	$2.45M	Buy	+60,495	New	+$2.72M	0.01%	805
2024 Q4	–	Sell	-47,060	Closed	-$1.55M	–	1630
2024 Q3	$1.55M	Sell	47,060 -38,263	-45%	-$1.08M	0.01%	739
2024 Q2	$2.32M	Sell	85,323 -11,724	-12%	-$394K	0.01%	611
2024 Q1	$3.53M	Buy	97,047 +6,964	+8%	+$205K	0.02%	509
2023 Q4	$1.82M	Buy	90,083 +49,382	+121%	+$825K	0.01%	694
2023 Q3	$723K	Buy	+40,701	New	+$720K	﹤0.01%	925

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TARS Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Tarsus Pharmaceuticals (TARS) stake by 18% in Q2 2026, selling an estimated $1.31M and leaving 90,969 shares worth $5.73M. The position accounts for 0.01% of the portfolio, ranked #681.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TARS in Q3 2023 and has held it in 10 quarters since. The position peaked at $14.2M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 90,969 shares of Tarsus Pharmaceuticals worth $5.73M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 20,468 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.31M.
Tarsus Pharmaceuticals made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #681 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Tarsus Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Tarsus Pharmaceuticals position peaked at $14.2M in Q4 2025.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.